TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ARV naïve subjects~* Documented HIV infection~* Documented TB infection~* Platelet count 40,000/mm3~* Hemoglobin ≥8.0 g/dL~* Absolute neutrophil count (ANC) \>500/mm3~* AST (SGOT), ALT (SGPT), and alkaline phosphatase \<3 X ULN~* Total bilirubin \<2.5 x ULN~* Calculated creatinine clearance ≥60 mL/min~* For women of reproductive potential, negative urine pregnancy test~Exclusion Criteria:~* Unable to provide informed consent.~* History drug abuse that the investigators suspect will interfere with compliance to study medications and visits.~* Patients on hemodialysis.~* Tuberculosis meningitis.~* Women with CD4 \> 250 and men with CD4 \> 400 due to higher risk of hepatotoxicity related to use of NVP.~* Positive serology for hepatitis C.~* Evidence for active hepatitis B including positive serologies for HBsAg, HBeAg, or HBV-DNA. Note: If anti-HBs is positive, patient is eligible for study if liver enzymes are within the parameters indicated in the inclusion criteria~* Women who are breast-feeding~* Known allergy/sensitivity to study drug(s) or their formulations~* Patients with other OIs or intercurrent illness that could affect their ability to take study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
- 2 (Type: EXPERIMENTAL): High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
- 3 (Type: ACTIVE_COMPARATOR): Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
- 4 (Type: EXPERIMENTAL): High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Surveillance For New Lung Primaries

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History squamous cell NSCLC who have undergone complete resection or definitive chemotherapy~Exclusion Criteria:~* History of an aerodigestive tract carcinoma of non-squamous histology~* Patients who have Stage IIIA, IIIB or IV squamous cell lung cancer that have undergone resection or chemotherapy within three years~* Patients who have Stage I or II squamous cell lung cancer that have undergone resection or chemotherapy within one year~* Patients who have received external beam radiation therapy for treatment of a squamous cell cancer of the lung

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescence bronchosopy with sputum cytology (Type: None): Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* FIGO stage III uterine carcinoma~* candidates for combined modality treatment (surgery, chemotherapy with carbo/Taxol, and radiation therapy)~Exclusion Criteria:~* Patients who are not FIGO stage III~* patients with carcinosarcoma histology~* patients who are ineligible for combined modality treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Quality of life evaluation (Type: EXPERIMENTAL): This prospective arm will consist of evaluating quality of life outcomes in women in women with advanced endometrial cancer undergoing adjuvant concurrent chemotherapy with carbo/Taxol and radiation therapy. Assessments will occur following surgery (baseline), 3, 6, 12, and 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients that meet the classic diagnosis of A-T and for whom the underlying mutation(s) is known. The diagnosis of A-T has been made by the clinician using the following criteria:~1. Characteristic neurological abnormalities, including but not limited to oculomotor apraxia, bulbar dysfunction, postural instability, and ataxia.~2. Presence of telangiectasia on the conjunctivae and/or skin.~3. Laboratory abnormalities including but not limited to elevated serum alpha-feto- protein, level, absence of ATM on western blot, increased x-ray induced chromosomal breakage in comparison to a control population, mutations in both alleles of the ATM gene. Parents of the patients above, who are haploinsufficient and whose mutation is known.~Exclusion Criteria:~Patients under 2 years of age No subjects will be excluded on the basis of age, sex, race, or socio-economic status.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- iPSCs without gene correction (Type: OTHER): This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
- iPSCs with gene correction (Type: OTHER): This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Electronic Deprescribing Tool for the Prevention of PIP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients ≥65 years who have been taking Benzodiazepines or/and Non-benzodiazepine hypnotics for at least 3 months and who do not meet any exclusion criterion~Exclusion Criteria:~* incapacity or unwillingness to provide written informed consent. Patient with dementia, psychotic disorder, a severe personality disorder; institutionalization; terminal illness, seizure disorders, rapid eye movement sleep disorders, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, epilepsy and periprocedural anesthesia

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Electronic Deprescribing tool (Type: EXPERIMENTAL): GPs of enrolled patients with access to the electronic Deprescribing tool
- Usual Care (Type: NO_INTERVENTION): Usual care By GP´s

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Hemophilia A patients who have switched treatment to treatment with Kovaltry or Jivi within the past 50 weeks, who are enrolled the ATHN 2: Factor Switching Study, and who have consented to participate in the Kovaltry or Jivi specific module will be included in this study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient/caregiver of Kovaltry or Jivi (Type: None): Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
- Physician Group (Type: None): Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MultiHance in Pediatric Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between 2 and 17 years of age~* Informed consent from parents~* Assent from patient where required~* Known or highly suspected disease of the CNS and referred for either cranial or spinal MRI examination~Exclusion Criteria:~* Contraindication to MRI~* Undergoing MRI in an emergency situation~* Known allergy to one or more of the ingredients in MultiHance~* Sickle cell anemia moderate to severe renal impairment~* Received another investigational compound within 30 days~* Pregnancy~* Lactating females~* Likely to undergo an invasive procedure within 72 hours of receiving MultiHance

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Gadobenate Dimeglumine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapy Coil Electrogram Collection Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is willing to sign and date the study Informed Consent form~* Subject is at least 18 years of age (or older, if required by local law)~* Subject is willing and able to wear a Holter monitor for up to 24 hours~* Subject has been implanted with a Medtronic ICD or CRT-D device~* Subject has an increased risk of lead insulation breach~Exclusion Criteria:~* Subject has medical conditions that would limit study participation~* Subject is enrolled in one or more concurrent studies that would confound the results of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No treatment (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed consent form~* Male and female between 18 - 50 years old~* AOH stage 1 or 2 according to Ficat~* Pain VAS scale \>40 mm (0-100)~Exclusion Criteria:~* Specific aetiology of AOH already known~* Cardiac and lung uncontrolled diseases~* Active malignancy untreated~* Hyper sensibility or allergy already known to ibandronate~* Pregnancy or breast feeding~* Severe kidney insufficiency (cl\<30 ml/min)~* Contra-Indications to an MRI (Pacemaker, cochlear implant...)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Unique perfusion of ibandronate 3 mg IV
- Placebo (Type: PLACEBO_COMPARATOR): Unique perfusion of NaCl 3mg IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study on Ennovate® Pedicle Screw Fixation in Isthmic Spondylolisthesis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic single-level IS (L4-S1), (VAS \> 30mm, treated conservatively for a minimum of 6 months)~* Isthmic Spondylolisthesis Meyerding grade I and II~* Signed Informed Consent of the patient regarding the participation in this study~Exclusion Criteria:~* Multilevel IS~* Severe degenerative changes of cranial adjacent level (disc height of \<50% of the next healthy segment,~* Previous lumbar spine surgery except microdiscectomy or micro- decompression of the index level~* Patients psychically or mentally not able to give or refuse consent~* Patients psychically or mentally not able to answer the questions regarding their health status and quality of life~* Pregnancy (current or planned)~* BMI \>35~* Systemic or local infection~* Chemotherapy or radiation ongoing~* Desire of early retirement (running pension request)~* All contraindications as listed in the instructions for use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ennovate (Type: None): Implantation of an Ennovate® internal fixation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Proven NSCLC or pulmonary metastases from extra-thoracic primary tumor~* Must be eligible for curative lung resection (lobectomy)~* Tumor/lesion size will be a minimum of 10mm along the minor diameter~* Willing to participate in all aspects of study protocol for duration of the study~* Able to understand study requirements~* Signs informed consent form~Exclusion Criteria:~* Any contraindication to bronchoscopy, for example:~  * Untreatable life-threatening arrhythmias.~ * Inability to adequately oxygenate the patient during the procedure.~ * Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated).~ * Recent myocardial infarction.~ * Previously diagnosed high-grade tracheal obstruction.~ * Uncorrectable coagulopathy~* Known coagulopathy~* Platelet dysfunction or platelet count \<100 x 10\^3 cells/mm3~* History of major bleeding with bronchoscopy~* Suspected pulmonary hypertension: additional testing required, such as ECG~* Moderate-to-severe pulmonary fibrosis~* Severe emphysema (GOLD III/IV) or chronic obstructive pulmonary disease (COPD):~additional testing and PI consent is required~* Bullae \>5cm located within the same lobe of target tumor/lesion~* Any other severe or life-threatening comorbidity that could increase the risk associated with bronchoscopic RFA~* Ongoing systemic infection~* Contraindications to general anesthesia~* Inability to stop anticoagulants or antiplatelet agents prior to procedure as dictated by the protocol~* Prior thoracic surgery on the same side of the lung as the targeted tumor/lesion~* Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study~* Life expectancy of less than one year.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Radio-frequency Ablation (Type: EXPERIMENTAL): Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Predictor for Cervix Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* cervix epidermoid cancer or adenocarcinoma : I to IIIB~* treatment by radiochemotherapy~* ECOG ≤ 1~* social and psychological compliance for standard treatment of radiochemotherapy for cervix carcinoma~* patient affiliated to health insurance system~* signed informed consent~Exclusion Criteria :~* contraindication to chemoradiotherapy~* resequable cervical cancer~* para-aortic metastases histologically proven~* inability to perform an abdominal MRI or a PET Scan~* contraindications related to MRI: pacemaker, vascular clip, and all devices incompatible with the electromagnetic field generated by MRI~* unbalanced diabete~* administration of EPO~* transfusion within 3 days before the first biopsy~* creatinine clearance under 60 mL / min;~* ANC \<1500 / mm3 and Platelets \<120,000 / mm3~* neuropathy, diabetes (fasting glucose greater than 140 mg / l) or any other condition that strongly contraindicates concomitant chemotherapy with radiotherapy~* sigmoid diverticulitis, Crohn's disease or systemic disease, collagenose

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- local control 19.8Gy (Type: EXPERIMENTAL): local control at 19.8 Gy, at Day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Two Medical Treatments for Early Pregnancy Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Early pregnancy failure, 6-14 weeks postmenstrual with~* a crown-rump length ≥ 6mm and no cardiac activity OR~* a crown-rump length \<6mm and no fetal growth at least one week later OR~* a gestational sac with absent embryonic pole for at least one week.~  * At least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age~ * Intra-uterine pregnancy~ * Women aged above 16 years~ * Hemodynamic stable patient~ * No signs of infection~ * No signs of incomplete abortion~ * No contraindications for mifepristone or misoprostol~Exclusion Criteria:~* Patient does not meet inclusion criteria, discovered after randomization~* Inability to give informed consent~* Known clotting disorder or use of anticoagulants~* Known risk factors for, or presence of, a cardiovascular disease~* Language barrier

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: PLACEBO_COMPARATOR): Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
- Misoprostol and Mifepristone (Type: EXPERIMENTAL): Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female subjects, 18-65 years of age with a diagnosis of SPMS~* HLA DR2 and/or DR4 positive~* Absence of a relapse in the 3 months prior to baseline~* EDSS of 3.0 - 6.5~Exclusion Criteria:~* Therapy with Beta-interferon, glatiramer acetate within 3 months or mitoxantrone, cyclophosphamide, methotrexate, azathioprine or any immune modulating or immunosuppressive drugs within 6 months of baseline~* Treatment with Tysabri within 2 years of baseline~* Females who are breast feeding, pregnant (pregnancy test at baseline) or not using a medically approved method of contraception regularly~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy